The relative contribution of CYP2C9 allelic variants to the pharmacokinetics (PK) of ibuprofen (IBP) enantiomers has been studied extensively, but the potential clinical benefit of pharmacogenetically guided IBP treatment is not evident yet. The role of AKR1D1*36C>T (rs 1872930) allelic variant in interindividual variability of CYP450 mediated drug metabolism was recently elucidated. A total of 27 healthy male subjects, volunteers in IBP single-dose two-way cross-over bioequivalence studies were genotyped for CYP2C9*2, CYP2C9*3 and AKR1D1*36 polymorphisms. The correlation between CYP2C9 and AKR1D1 genetic profile and the PK parameters for S-(+) and R-(-)-IBP was evaluated. Remarkable changes in the PK values pointing to reduced CYP2C9 enzyme activity were detected only in the CYP2C9*2 allelic variant carriers. Statistically significant association between the AKR1D1*36 allele and the increased IBP metabolism (low AUC 0-t and 0-∞ , high Cl tot and short t max values for both enantiomers) was observed in subjects carrying the CYP2C9 *1/*3 or CYP2C9*1/*1 genotype. The clinical value of concomitant CYP2C9 and AKR1D1 genotyping has to be further verified.
diastereoisomeric mixture, which comprises a S-(+) moiety and a R-(-)enantiomer moiety. S-(+)-IBP is pharmacologically more active as a prostaglandin (PG) synthesis inhibitor; however, R-(-)-IBP has pharmacological properties relevant to the anti-inflammatory activity of IBP. In humans, R-(-)-IBP undergoes extensive enantiomeric conversion to the S-(+)
isomer and both isomers are metabolized extensively to inactive metabolites. Thus, the contribution of each of the isomers to the anti-inflammatory, analgesic and antipyretic effects of IBP underlines the interrelation between the PK/metabolism of IBP and its pharmacodynamics (PD) (1, 3, 4) . When orally administered, IBP is rapidly absorbed from the upper gastrointestinal tract, with the maximum time to reach the maximum plasma concentration (t max ) of approximately 1-2 h. Depending on the release characteristics of the formulation, various plasma S/R ratios have been observed, namely, higher with modified--release compared to conventional release, i.e. immediate-release formulations. The bio distribution of IBP is characterized by high plasma protein binding and low distribution volume (V d ), with significant accumulation in inflamed compartments. In subjects with preserved renal and liver functions, IBP exhibits linear kinetics when taken in up to 1200 mg (repeated) doses. Plasma concentration (C p ) and, to some extent, the area under the curve (AUC) values are dose-related, but with little variation with (repeated) dosage as suggested by the kinetic constants, elimination half-life (t 1/2 )/elimination rate constant (K el ). The non-linear PKs occurring at high doses is due to the saturation of plasma protein binding. The plasma half-life of IBP is between 2 and 3 h on average, with excretion being complete after 24 h of the last IBP dose administration. The relatively fast rate of absorption of IBP is followed by a systematic metabolism of both enantiomers, which are extensively (99 %) metabolized to their major chiral, pharmacologically inactive 2-hydroxyl, 2-carboxyl and glucuronide metabolites via CYP450 (CYP2C8 and 2C9) mediated oxidation and UGT (UGT2B7) mediated glucuronidation. Half-lives of the S-(+)-IBP, 2-hydroxylated or carboxylated glucuronides are approximately 3.7 h and about 1.7 h (1,5-8) of R-(-)-IBP acyl glucuronides. CYP2C9 has been identified as the most important catalyst for the formation of all oxidative metabolites of IBP enantiomers, though it is mainly involved in the hydroxylation of S-(+)-IBP, while CYP2C8 preferentially metabolizes R-(-)-IBP (8) (9) (10) . Polymorphisms in CYP2C8 and CYP2C9 gene (*2 and *3 allelic variants) coding for the corresponding enzymes are among the identified factors with a direct impact on the PK of IBP and thus on the variability in drug response and adverse drug events (11) . Major adverse events affect the gastrointestinal tract (GIT), kidneys and the coagulation system. Chronic treatment with IBP is a potential reason for the occurrence of GI bleeding, increased risk of gastric ulcers and damages and also of epistaxis, heart failure, hyperkalemia, confusion and bronchial spasms. Other adverse reactions, though very rare, were also reported, including renal adverse events such as acute renal failure, interstitial nephritis and nephritic syndrome (12) (13) (14) (15) . The incidence and intensity of ADE might vary significantly due to the CYP2C8/C9 stereospecific preference of IBP (11) . However, information on interindividual variability of pharmacokinetic parameters related to the safety profile of IBP and its enantiomers is limited. Published results on the CYP2C8/C9 genetic impact on IBP metabolism are mainly inconclusive and open to doubt, mostly because of the incomplete genotype effect observed in studies with small healthy cohorts and/or heterogeneous cohorts and also because of the difficulty to distinguish the CYP2C8/C9 allelic variant effects on the IBP enantiospecific metabolism due to the high sequence homology between the two genes (16) (17) (18) . Moreover, it has been found that the amount of active CYP2C9 enzyme depends on the level of gene expression, the rates of mRNA transcription and degradation, protein degradation, the presence of enzyme inhibitors/antagonists and post-transcriptional regulation of CYP2C isoforms by microRNAs. The amount of protein of other CYP isoforms (CYP2D6, CYP3A4) might also influence CYP2C9 enzyme activity via protein-protein interactions (19) . In addition, the acylation of proteins to form adducts from the reaction of acyl glucuronides of ibuprofen may be of relevance for adverse reactions in the liver analogous to those occurring with some other NSAIDs, though evidence for this is still lacking (1) . Overall, even when CYP2C9 enzyme involvement is major, each COX inhibitor has to be evaluated on an individual basis, taking into account the available data related to all clearance mechanisms, direct conjugation and especially non-P450 oxidation (20) .
A recently published study by Chandry et al. (21) provided a new insight, which can account for interindividual differences in CYP450 drug metabolism, drug efficacy and adverse drug events. The authors obtained experimental evidence supporting the putative role of the AKR1D1 gene as a trans-genetic regulator of the CYP network and pointed to the significant association between AKR1D1*36 C>T (rs1872930) allelic variation, augmented hepatic CYP450 mRNA expression and increased activity of AKR1D1, CYP2C9 and CYP2C8 enzymes coded by the corresponding genes. AKR1D1 catalyzes the NADPH dependent reduction of bile acids and steroids but it is also involved in the reduction of either carbonyl groups or α,β-unsaturated ketones on a variety of xenobiotics (dicarbonyls and polycyclic aromatic hydrocarbon trans-dihydrodiols, including a great variety of nonsteroidal aldehydes and ketones (22) . Hence, it is plausible that the AKR1D1*36 C>T (rs1872930) polymorphism may contribute to the observed interindividual variability of IBP PK and the associated drug response. These recent findings are of particular importance since the most common CYP2C8/C9 cis-variations, independently and together, do not explain clearly the patient-to-patient inconsistency in the metabolism of IBP enantiomers. Despite the availability of numerous studies evaluating the genetic factors associated with interindividual variability of the IBP metabolism, there are no reported studies about the impact of AKR1D1*36C>T on the metabolism of S-(+) and R-(-)-IBP. Having all this in mind, our pilot study aims to evaluate the separate and appraise the combined genetic impact of CYP2C9 and AKR1D1 variant alleles on the pharmacokinetics of ibuprofen enantiomers in healthy male volunteers from The Republic of Macedonia.
EXPERIMENTAL

Study population
The study sample comprised 27 healthy Caucasian male volunteers according to the medical history, ECG, vital signs, laboratory data and physical examination (non-smokers, None of the participants were related; they were fully informed about the nature of both PK and pharmacogenetic (PGx) studies, gave their written informed consent and could discontinue their participation at any time during the trials. None of the subjects participated in more than one trial. The exclusion criteria of interest were clinically significant illnesses and surgery within 4 weeks prior to the first dosing; clinically significant abnormalities of medical history (neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic diseases) at physical examination, of the ECG, of hematology, biochemistry or urinalysis results; history of hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response to aspirin or other NSAIDs; history of recurrent peptic ulcer/hemorrhage; history of GI disease (ulcerative colitis, Crohn's disease); history of GI bleeding or perforation related to previous NSAID therapy; positive alcohol test at Check-in (Day-1) and history of alcohol and/or drug abuse within one year prior to the screening; use of investigational drugs within 28 days (4 weeks) or any drugs known to induce or inhibit hepatic drug metabolism within 28 days (4 weeks) prior to the first administration of the study medication and participation in other clinical studies within 2 months before the study.
Bioequivalence trials design and procedures
All four IBP bioequivalence trials were designed as single-center, randomized, open--label, two-way cross-over bioequivalence studies of the oral, immediate-release formulation of IBP with systemic action (with identical contents of both enantiomers), following a single dose administration under fasting conditions. The IBP plasma concentrations of 12 subjects receiving 400 mg, 10 subjects participating in the studies with 375 mg, 2 subjects receiving 200 mg and 3 subjects receiving 100 mg oral IBP were used in the PK analysis. According to the study protocols, a total of 20 blood samples were collected in each period: pre-dose and 0.083, 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 14 hours post-dose. An additional blood sample was collected at Check-in (Day-1) of Period 1 for the investigation of potential pre-dose concentrations and this sample was not used for pharmacokinetic evaluation. The subjects remained at the clinical unit during the whole period, i.e. until the collection of the 14 h post drug blood sample. The samples were centrifuged at 4 °C for 10 min at 3500 rpm and plasma aliquots (labeled with the protocol code, the subject number, the period and the time at which the sample was obtained) were stored at -30 °C until further analytic determinations.
Pharmacokinetic analysis
Concentrations of R-(-)-IBP and S-(+)-IBP
were determined using validated high-performance liquid chromatography coupled with a tandem mass spectrometry detection (HPLC MS/MS) chiral method according to Nakov et al. (23) . Estimation of the PK parameters was performed from the plasma concentration-time dependent data by a standard non-compartmental method using Pharsight ® Knowledgebase ServerTM and Phoenix
. Maximum plasma concentration (c max ) and t max were obtained directly from raw data. The area under the curve to the last measured concentration (AUC 0-t ) was calcu-lated by linear trapezoidal integration. The area under the curve extrapolated to infinity (AUC 0-∞ ) was calculated as the sum of AUC 0-t and the residual area (c t divided by K el , with c t as the last measured concentration and K el as the elimination rate constant). Because of different doses administered in different trials, AUC and c max were divided by the dose according to the body weight (mg kg . Total drug clearance adjusted for bioavailability (Cl tot ) was calculated by dividing the dose by AUC and weight-adjusting.
CYP2C9 and AKR1D1 genotyping
Genomic DNA was isolated from 3 mL whole blood (collected in an EDTA blood tube) using proteinase K digestion/phenol-chloroform extraction and ethanol precipitation and stored at 4 °C until genotyping. The obtained DNA was spectrophotometrically quantified on Nano Drop ® and its purity was verified using a 260/280 nm ratio. DNA integrity was confirmed by 0.8 % agarose electrophoresis, stained with ethidium bromide. Identification of CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910) and AKR1D1*36C>T (rs1872930) variant alleles was done with a real-time polymerase chain reaction [MxPro 3005P, Stratagene, La Jolla, CA, USA] using TaqMan SNP and drug metabolism genotyping assays according to the manufacturers' instructions [Applied Biosystems, Foster City, CA, USA]. The CYP2C9 and AKR1D1 genotyping was performed at the Center for Biomolecular and Pharmaceutical Analysis, Faculty of Pharmacy, University "Ss Cyril and Methodius" in Skopje, Macedonia.
Statistical analysis
The Hardy-Weinberg equilibrium was estimated for all analyzed variants. Deviations from the equilibrium were detected by comparing the observed and expected frequencies using Fisher's exact test. Pearson's chi-square test was used for evaluation of differences in the CYP2C9 and AKR1D1 allelic and genotypic frequencies between the study subjects and those reported for the Macedonian population. Values of PK parameters were expressed as mean ± SD. All statistical analyses were performed using MedCalc 14.12.0 and StatGraph17. 
RESULTS AND DISCUSION
Pharmacokinetic parameters
Interindividual variability in the PK parameters for IBP enantiomers, present at identical concentrations in the administered racemic product, was investigated in 27 healthy volunteers. Mean values of the PK parameters are summarized in Table I Genotyping for CYP2C9 and AKR1D1 alleles CYP2C9 and AKR1D1 allelic frequencies and genotype distributions in the considered population of healthy volunteers (N = 27 subjects) are presented in Table II . All investigated genetic variants (CYP2C9*2, CYP2C9*3 and AKR1D1*36C>T) were in Hardy-Weinberg equilibrium (p = 0.558, p = 0.639, p = 0.936, respectively) and their frequencies were in accord with those reported for the population of The Republic of Macedonia (p = 0.342 for CYP2C9*2, p = 1 for CYP2C9*3 and p = 0.664 for AKR1D1*36C>T) (24, 25) . No homozygosity for the variant CYP2C9 *2 and *3 alleles (*2/*2 and *3/*3 genotype) was detected and none of the subjects was identified as a carrier of both CYP2C9 variant alleles (*2/*3 genotype) in this study. This finding was expected taking into account the small sample size as well as the fact that the prevalence of these functionally significant genotypes in most populations, including the Macedonian, is below 0.05.
Evaluation of CYP2C9 PGx/PK relationship
The time dependent plasma concentration curves of both IBP enantiomers according to the CYP2C9 genotype are shown in Fig. 1 . The observed effects were similar to previously published reports (9, (26) (27) (28) , suggesting that both CYP2C9 *2 and *3 alleles reduce enzyme activity. Pharmacokinetic parameters derived from a non-compartmental analysis of individual data are presented in Table III . Significant differences across the three genotype groups regarding S-(+)-IBP for AUC 0-t (p = 0.016), AUC 0-∞ (p = 0.019), Cl tot (p = 0.022) and c max (p = 0.039) were observed. Pairwise comparisons revealed that the subjects with the CYP2C9 *1/*2 genotype had 25 % lower Cl tot and 14 % higher c max compared to subjects with the CYP2C9 *1/*1 CYP2C9 *1/*3 genotype. CYP2C9 *1/*2 had markedly higher AUC 0-t and AUC 0-∞ values (25 % higher) than those found for CYP2C9*1/*1.
In case of R-(−)-IBP, significant differences across the three genotype groups regarding
Cl tot (p = 0.001), c max (p = 0.023), K el (p = 0.024) and t 1/2 (p = 0.024) were identified. Pairwise (9, 16, 27) , our data suggest a stronger impact on IBP PK for CYP2C9 *2 compared to the CYP2C9*3 allele. This might be attributed to the underrepresentation of homozygotes for the variant alleles (*2/*2;*3/*3 and *2/*3 genotypes) considering that changes in PK parameters are proportional to the number of CYP2C9 variant alleles (20) . Moreover, they suggest that even though CY-P2C9 is considered a major genetic factor for R-(-) and S-(+)-IBP clearance, the effect of CYP2C8 should also be measured since CYP2C8 *3 alone or in combination with CYP2C9 *2 has a more significant impact on IBP AUC and clearance than CYP2C9 *3 (26, 27, 29, 30) . Bearing in mind the high sequence homology between CYP2C9 and CYP2C8 as well as the recognized LD between the CY-P2C8*3 and CYP2C9*2 alleles; where 96 % of the subjects with the CYP2C8*3 allele also carry CYP2C9*2 and 85 % of the subjects with CYP2C9*2 variant also have a CYP2C8*3 (17, 18), we did not assess the effect of CYP2C8 polymorphism on IBP enantiomeric metabolism. However, the results obtained are in agreement with those previously reported by Rodrigues and Rushmore (31) , which proved that when evaluating only the CYP2C9 genotype status, there is no significant difference in IBP PK parameters between subjects genotyped as CYP2C9 *1/*3 and *1/*1.
CYP2C9 genotypes and pharmacokinetic parameters (mean ± SD) for S-(+) and R-(-)-IBP in the study population CYP2C9
Although the differences observed in PK parameters, especially clearance, after oral administration in subjects with different CYP2C9 genotypes (dominantly carriers of CY-P2C9 *2/*2; *2/*3 and *3/*3), suggest that the safety and efficacy of CYP2C9 substrates could be improved by drug dose adjustment (32, 33) and since the correlation between the genotype and phenotype is not clear, prospective evaluations of this strategy are needed before establishing its clinical utility.
Evaluation of AKR1D1 PGx/PK relationship
Data regarding the impact of the AKR1D1 genetic variant on the IBP enantiomeric metabolism are summarized in Table IV . Careers of *36 allele had significantly higher Cl tot and notably shorter t max for both IBU enantiomers compared to wild type carriers (p < 0.001). Furthermore, AKR1D1 *36 allele was associated with significantly lower AUC (0-t and 0-∞) values but only in regard to S-(+)-IBP. We observed that the increased AKR1D1 enzyme activity in the metabolic biotransformation of IBU enantiomers was not proportional to the number of *36 variant alleles. For S-(+)-IBP, the genotype model of analysis showed significant differences across the three genotype groups regarding AUC 0-t and AUC 0-∞ (p < 0.001, for all), Cl tot and t max (p < 0.001). The post hoc Dunn test revealed that the AKR1D1 *1/*36 genotype was associated with higher Cl tot and shorter t max values compared to the AKR1D1 *36/*36 genotype and lower AUC ( 0-t and 0-∞ ) values than those found for AKR1D1 *1/*1 and AKR1D1 *36/*36 genotypes. The same pattern of significant alterations (p < 0.001) regarding AUC (0-t and 0-∞) , Cl tot and t max across the three genotypes was observed for R-(−)-IBP.
Since we had established previously that CYP2C9 *2 had a marked effect on IBP PK while the effect of *3 allele was indistinct, we supposed that the CYP2C9 genotype confounded the association between AKR1D1*36 and IBP PK parameters. Therefore, an additional analysis was performed to assess the impact of the AKR1D1 *36 variant allele but only in subjects who are not carriers of the CYP2C9 *2 allele (Table V) . In these subjects, the carriers of AKR1D1*36 allele had significantly lower AUC( 0-t and 0-∞ ), higher Cl tot and shorter t max values for both S-(+)-IBP and R-(-)-IBP. Interestingly, in this sub-stratification analysis, the differences for IBP PK parameters were proportional to the number of the AKR1D1*36 alleles. A statistically significant variation across the three genotypes regarding AUC( 0-t and 0-∞ ) Cl tot and t max (p < 0.001) was found for both IBP enantiomers. Pairwise comparisons showed that the AKR1D1 *36/*36 genotype was associated with increased metabolic biotransformation of IBP compared to other AKR1D1 genotypes. These results confirmed our initial assumption regarding the clear influence of the CYP2C9*2 allelic variant on IBP PKs and highlights the distinct role of AKR1D1*36C>Т in the metabolism of IBP.
The present study is the first to investigate the relationship between AKR1D1*36C>T (rs1872930) and the combined AKR1D1/CYP2C9 effect on the PK of IBP enantiomers. Regarding the contribution to previous knowledge (19, 21) and our expectations, it is still unclear whether the AKR1D1*36 C>T (rs1872930) allelic variant influences CYP2C9 enzyme activity (i.e. catalytic activity, kinetics), or the expression of CYP2C9 mRNA, and consequently enzyme activity. Future studies specifically designed to answer this questions of broader biological relevance would be very interesting. However, the results obtained in the present study support the data published by Chaundry et al. (21) and Tracy et al. (19) and add to the evidence that genetic variation in genes, like AKR1D1, is an important contributor to variation in CYP450 activity, by influencing the level of ligands that activate nuclear receptors responsible for the transcriptional regulation of P450s (e.g., bile acids).
genetic variant and pharmacokinetic parameters (mean ± SD) for S-(+) and R-(-)-IBPin healthy volunteers (N = 27) S-(+)-IBP R-(-)-IBP
In this report, we provide evidence for the association between CYP2C9 cis-allelic variants, AKR1D1 trans-genetic regulator of CYP450 gene network and the PK profile of IBP enantiomers. A crucial observation from the study is the association between the AKR1D1 minor allele and the increased IBP metabolism in subjects who are carriers of CYP2C9 *1/*3 or CYP2C9 wild genotype. Our model implies that patients on a long-term IBP treatment who are not carriers of CYP2C9*2 allele require additional stratification according to the AKR1D1 genotype in order to avoid the risk of adverse IBP side events. A potential weakness of the current study is the small number of subjects. In the next phase of the project, we will further evaluate the value of concomitant CYP2C9 and AKR1D1 genotyping and conduct a reanalysis in a larger cohort of subjects with a higher representation of CYP2C8/C9 genotypes.
CONCLUSSIONS
The results from this pilot study contribute to the efforts aimed at clearer elucidation of the ibuprofen metabolic phenotype. They suggest that significant changes in the PK values associated with reduced CYP2C9 enzyme activity are anticipated to occur only in the carriers of the CYP2C9*2 allelic variant. AKR1D1*36 provides a new insight regarding the interindividual differences in the metabolism of the IBP enantiomers. The value of concomitant CYP2C9 and AKR1D1 genotyping has to be further proven in studies with a larger sample size and in prospective randomized clinical studies.
